PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle
- Conditions
- PainSprains and StrainsSprain
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 202
- Registration Number
- NCT00671320
- Locations
- 🇵🇪
Pfizer Investigational Site, Lima, Peru
Varenicline Observational Investigation In The Cessation of Smoking
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 567
- Registration Number
- NCT00669240
- Locations
- 🇸🇮
Pfizer Investigational Site, Maribor, Slovenia
A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: PF-04383119 (tanezumab)
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 83
- Registration Number
- NCT00669409
- Locations
- 🇯🇵
Medical Corporation Yamamoto Kinenkai Yamamoto Kinen Hospital, Yokohama-shi, Kanagawa-ken, Japan
🇯🇵Nippon Kokan Clinic, Kawasaki, Kanagawa, Japan
🇯🇵FuruKawabashi Hospital, Minato-ku, Tokyo, Japan
Bioequivalence Study Of Verapamil
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00668967
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
- Conditions
- Unresectable or Metastatic Colorectal Cancer
- Interventions
- Drug: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT00668863
- Locations
- 🇯🇵
Pfizer Investigational Site, Minoh/Osaka, Japan
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 901
- Registration Number
- NCT00667810
- Locations
- 🇺🇸
Clinical Trials, Inc., Little Rock, Arkansas, United States
🇺🇸Center for Healthy Aging, Greenwich, Connecticut, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1004
- Registration Number
- NCT00666276
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
- Conditions
- Dental Pain
- Interventions
- Drug: ARRY-371797, p38 inhibitor; oralDrug: Celecoxib, COX-2 inhibitor; oralDrug: Placebo; oral
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00663767
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
🇺🇸Lifetree Clinical Research, Salt Lake City, Utah, United States
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00663026
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Drug: Placebo for Fragmin/ Dalteparin Sodium
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 276
- Registration Number
- NCT00662831
- Locations
- 🇬🇧
Pfizer Investigational Site, Peterborough, United Kingdom